Risk of thyroid cancer, brain cancer, and NHL in Danish adults after a diagnosis of leukemia matched with 5 controls from the general population
| . | n . | Thyroid cancer . | Brain cancer . | All . | NHL B-cell . | T-cell . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n . | HR . | 95% CI . | n . | HR . | 95% CI . | n . | HR . | 95% CI . | n . | HR . | 95% CI . | n . | HR . | 95% CI . | ||
| Adult leukemia | 18 834 | 18 | 4.9 | 2.8-8.5 | 21 | 1.9 | 1.2-3.1 | 66 | 3.3 | 2.5-4.4 | 50 | 3.4 | 2.5-4.7 | 1 | 0.5 | 0.1-4.1 |
| CLL | 8582 | 10 | 4.5 | 2.0-9.8 | 13 | 1.7 | 1.0-3.2 | 57 | 3.4 | 2.5-4.6 | 46 | 3.9 | 2.7-5.6 | 1 | 0.5 | 0.1-4.3 |
| Non-CLL | 10 252 | 8 | 6.9 | 3.0-16 | 8 | 2.3 | 1.1-4.9 | 9 | 1.9 | 1.0-3.9 | 4 | 1.1 | 0.4-3.1 | 0 | NE | |
| ALL | 789 | 0 | NE | 1 | 3.7 | 0.4-33 | 0 | NE | 0 | NE | 0 | NE | ||||
| AML | 5708 | 3 | 5.9 | 1.6-20 | 4 | 3.0 | 1.1-8.7 | 1 | 0.5 | 0.1-3.1 | 1 | 0.7 | 0.1-5.6 | 0 | NE | |
| CML | 2005 | 3 | 15 | 2.8-81 | 2 | 4.1 | 0.8-21 | 1 | 1.6 | 0.2-13 | 0 | NE | 0 | NE | ||
| Other | 1750 | 2 | 11 | 1.7-70 | 1 | 1.0 | 0.1-8.1 | 7 | 4.4 | 1.7-11 | 3 | 3.0 | 0.8-11 | 0 | NE | |
| Childhood leukemia† | 1228 | 1 | 10 | 0.4-223 | 6 | 7.2 | 2.0-26 | 1 | 6.5 | 0.4-110 | 1 | 6.5 | 0.4-110 | 0 | NE | |
| Childhood leukemia* | 12 731 | 9 | 19 | 4.3-36 | 19 | 8.5 | 5.1-13 | 9 | 9.4 | 4.3-18 | 0 | NR | 0 | NR | ||
| . | n . | Thyroid cancer . | Brain cancer . | All . | NHL B-cell . | T-cell . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n . | HR . | 95% CI . | n . | HR . | 95% CI . | n . | HR . | 95% CI . | n . | HR . | 95% CI . | n . | HR . | 95% CI . | ||
| Adult leukemia | 18 834 | 18 | 4.9 | 2.8-8.5 | 21 | 1.9 | 1.2-3.1 | 66 | 3.3 | 2.5-4.4 | 50 | 3.4 | 2.5-4.7 | 1 | 0.5 | 0.1-4.1 |
| CLL | 8582 | 10 | 4.5 | 2.0-9.8 | 13 | 1.7 | 1.0-3.2 | 57 | 3.4 | 2.5-4.6 | 46 | 3.9 | 2.7-5.6 | 1 | 0.5 | 0.1-4.3 |
| Non-CLL | 10 252 | 8 | 6.9 | 3.0-16 | 8 | 2.3 | 1.1-4.9 | 9 | 1.9 | 1.0-3.9 | 4 | 1.1 | 0.4-3.1 | 0 | NE | |
| ALL | 789 | 0 | NE | 1 | 3.7 | 0.4-33 | 0 | NE | 0 | NE | 0 | NE | ||||
| AML | 5708 | 3 | 5.9 | 1.6-20 | 4 | 3.0 | 1.1-8.7 | 1 | 0.5 | 0.1-3.1 | 1 | 0.7 | 0.1-5.6 | 0 | NE | |
| CML | 2005 | 3 | 15 | 2.8-81 | 2 | 4.1 | 0.8-21 | 1 | 1.6 | 0.2-13 | 0 | NE | 0 | NE | ||
| Other | 1750 | 2 | 11 | 1.7-70 | 1 | 1.0 | 0.1-8.1 | 7 | 4.4 | 1.7-11 | 3 | 3.0 | 0.8-11 | 0 | NE | |
| Childhood leukemia† | 1228 | 1 | 10 | 0.4-223 | 6 | 7.2 | 2.0-26 | 1 | 6.5 | 0.4-110 | 1 | 6.5 | 0.4-110 | 0 | NE | |
| Childhood leukemia* | 12 731 | 9 | 19 | 4.3-36 | 19 | 8.5 | 5.1-13 | 9 | 9.4 | 4.3-18 | 0 | NR | 0 | NR | ||
All hazard ratios are multivariate adjusted for age, sex, descent, geographic residency, highest level of education, birth year, and age at diagnosis for the leukemia patient.
NE indicates not available because of no events among those with leukemia; and NR, not reported in the paper.
Hazard ratio from own data.
Standardized incidence ratios and data from Maule et al.5